Emalex is in a late-stage clinical study of a new class of drug for patients with Tourette syndrome who have limited treatment options.
Latest News
Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.
At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.
We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.
Latest News
Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.
At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.
We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
By emalexadmin |
Currently, we are investigating therapies for Tourette syndrome in pediatric patients and childhood-onset fluency disorder—also known as stuttering—in adults. To date, there is only one U.S. Food and Drug Administration (FDA)-approved treatment for Tourette’s and no FDA-approved treatment for childhood-onset fluency disorder.
Did you know that approximately 1 out of every 160 children (ages 5-17) in the U.S. has TS?
For more than 50 years, the Tourette Association of America (TAA) has provided support for people living with TS and other tic disorders.
At Emalex Biosciences, we are working diligently to help people with TS find relief from tics that not only often cause pain and injury but also social stigma and emotional distress.
We kick-off our series that explores the life and world of people living with TS starting with TAA President and CEO Amanda Talty.